Halozyme Therapeutics Inc (NASDAQ:HALO)

45.51
BATS BZX Real-Time Price
As of 3:15pm ET
 -0.90 / -1.94%
Today’s Change
12.71
Today|||52-Week Range
56.40
+6.56%
Year-to-Date
Why Halozyme Therapeutics Is Trading 14% Higher Today
Feb 24 / MotleyFool.com - Paid Partner Content
Halozyme Therapeutics Inc (HALO) Q4 2020 Earnings Call Transcript
Feb 23 / MotleyFool.com - Paid Partner Content
Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls
Feb 24 / Zacks.com - Paid Partner Content
Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More
Feb 22 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close46.41
Today’s open46.24
Day’s range44.67 - 46.72
Volume48,161
Average volume (3 months)1,868,950
Market cap$6.1B
Data as of 3:15pm ET, 03/02/2021

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)+73.32%
Earnings growth (next 5 years)+59.50%
Revenue growth (last year)+36.53%
P/E ratio50.0
Price/Sales22.58
Price/Book40.55

Competitors

----
KODKodiak Sciences Inc-9.02-6.68%
BPMCBlueprint Medicines ...-0.29-0.29%
IOVAIovance Biotherapeut...-1.96-4.97%
Data as of 3:15pm ET, 03/02/2021

Financials

Next reporting dateMay 11, 2021
EPS forecast (this quarter)$0.32
Annual revenue (last year)$267.6M
Annual profit (last year)$129.1M
Net profit margin48.24%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
--, --

Forecasts